{rfName}
Me

Indexed in

License and use

Icono OpenAccess

Citations

14

Altmetrics

Grant support

Alcida Karz: SPORE P50 CA225450; Maya Dimitrova: None; Kevin Kleffman: SPORE P50 CA225450; Christopher Alvarez-Breckenridge: K12NS080223; Michael B. Atkins: NCI P30 CA051008 to the Georgetown Lombardi Comprehensive Cancer Center; Adrienne Boire: NCI/NIH P30 CA008748, R01 CA245499; Marcus Bosenberg: None; Priscilla Brastianos: National Institutes of Health (5R01CA227156-04; 5R01CA244975-02), Breast Cancer Research Foundation, Demetra fund of the Hellenic Women's Association, and the Terry and Jean de Gunzburg MGH Research Scholar Award; Daniel Cahill: None; Qing Chen: NIH NCI (R01CA241490); Sherise Ferguson; Peter Forsyth: NIH/NCI 1R21CA256289-01A1, R21CA252634-01A1, 1R01CA236034; DOD; Pfizer NCT03719768; Roswell Park; Isabella C. Glitza Oliva: none; Sarah Goldberg: None; Sheri Holmen: NIH/NCI R01CA121118, MRA 347651; Jonathan Knisely: None; Glenn Merlino: NIH Intramural Research Program; Don X. Nguyen: R01CA166376, R01CA191489, and P50CA196530; Michael Pacold: NCI R01 CA211687 (Philips), Damon Runyon-Rachleff Innovation Award DRR 63-20, MRA YIA 688365, Harry J. Lloyd Charitable Trust, ACS Research Scholar Grant RSG-21-115-01-MM, Irma T. Hirschl Career Scientist Award; Eva Perez-Guijarro: NIH Intramural Research Program. FLEX Synergy Award from the NCI Center for Cancer Research; Keiran Smalley: R21CA256289; Hussein Tawbi: None; Patrick Wen: None; Michael A. Davies: MAD is supported by Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH/NCI 1 P50 CA221703-02, the American Cancer Society and the Melanoma Research Alliance, Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson; Harriet M. Kluger: None; Janice M. Mehnert: None; Eva Hernando: SPORE P50 CA225450, and a joint Melanoma Research Alliance/American Cancer Society award.

Analysis of institutional authors

Perez-Guijarro, EvaAuthor

Share

Publications
>
Review

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

Publicated to:Pigment Cell & Melanoma Research. 35 (6): 554-572 - 2022-09-01 35(6), DOI: 10.1111/pcmr.13059

Authors: Karz, Alcida; Dimitrova, Maya; Kleffman, Kevin; Alvarez-Breckenridge, Christopher; Atkins, Michael B.; Boire, Adrienne; Bosenberg, Marcus; Brastianos, Priscilla; Cahill, Daniel P.; Chen, Qing; Ferguson, Sherise; Forsyth, Peter; Oliva, Isabella C. Glitza; Goldberg, Sarah B.; Holmen, Sheri L.; Knisely, Jonathan P. S.; Merlino, Glenn; Nguyen, Don X.; Pacold, Michael E.; Perez-Guijarro, Eva; Smalley, Keiran S. M.; Tawbi, Hussein A.; Wen, Patrick Y.; Davies, Michael A.; Kluger, Harriet M.; Mehnert, Janice M.; Hernando, Eva;

Affiliations

Abstract

Brain metastases are the most common brain malignancy. This review discusses the studies presented at the third annual meeting of the Melanoma Research Foundation in the context of other recent reports on the biology and treatment of melanoma brain metastases (MBM). Although symptomatic MBM patients were historically excluded from immunotherapy trials, efforts from clinicians and patient advocates have resulted in more inclusive and even dedicated clinical trials for MBM patients. The results of checkpoint inhibitor trials were discussed in conversation with current standards of care for MBM patients, including steroids, radiotherapy, and targeted therapy. Advances in the basic scientific understanding of MBM, including the role of astrocytes and metabolic adaptations to the brain microenvironment, are exposing new vulnerabilities which could be exploited for therapeutic purposes. Technical advances including single-cell omics and multiplex imaging are expanding our understanding of the MBM ecosystem and its response to therapy. This unprecedented level of spatial and temporal resolution is expected to dramatically advance the field in the coming years and render novel treatment approaches that might improve MBM patient outcomes.

Keywords

BrainBrain metastasesBrain neoplasmsDna-damageEcosystemGenomic characterizationHumansImmunotherapyIonizing-radiationLocal radiationMelanomaNeoplasms, second primaryOpen-labelPrognostic-factorsRadiation-therapyStereotactic radiosurgerySting pathwayTumor microenvironment

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Pigment Cell & Melanoma Research due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 13/70, thus managing to position itself as a Q1 (Primer Cuartil), in the category Dermatology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 1.52, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 5.31 (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-29, the following number of citations:

  • WoS: 1
  • Scopus: 10
  • Europe PMC: 3
  • OpenCitations: 6

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-29:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 42.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 40 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 11.8.
  • The number of mentions on the social network X (formerly Twitter): 17 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United States of America.